Patents Assigned to BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
  • Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
    Patent number: 11548900
    Abstract: Provided are an oxazino-quinazoline and oxazino-quinoline type compound, a preparation method, and uses thereof. More particularly provided is a compound shown in formula (I), an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, a prodrug thereof, a preparation method, and uses thereof in preparing a drug acting as a kinase inhibitor.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 10, 2023
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Nanqiao Zheng, Hailong Yang, Leifu Yang, Hongbo Zhang, Likai Zhou, Zhanqiang Xu
  • Urea-substituted aromatic ring-linked dioxinoquinoline compounds, preparation method and uses thereof
    Patent number: 11479559
    Abstract: The present invention relates to an urea-substituted aromatic ring-linked dioxinoquinoline compound of formula (I), or a pharmaceutically acceptable salt or a hydrate thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2, C-RAF, B-RAF, and RET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: October 25, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yansheng Liu, Xingfu Li, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Dioxinoquinoline compounds, preparation method and uses thereof
    Patent number: 11407760
    Abstract: The present invention relates to a dioxinoquinoline compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a preparation method of the compound of formula (I) and a pharmaceutically acceptable salt thereof, as well as uses thereof as a drug, wherein the drug acting as a tyrosine kinase (i.e. VEGFR-2 and c-MET) inhibitor is used for treating disorders related to tyrosine kinase.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 9, 2022
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Shannan Yu, Zhongxiang Wang, Shouye Feng, Yueming Sun, Yansheng Liu, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Chenming Hu, Zhanqiang Xu
  • Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
    Patent number: 10980809
    Abstract: The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.
    Type: Grant
    Filed: February 11, 2018
    Date of Patent: April 20, 2021
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Qiang Zhang, Hongbo Zhang, Leifu Yang, Hailong Yang, Likai Zhou, Nanqiao Zheng, Shannan Yu, Zhongxiang Wang, Shouye Feng, Zhanqiang Xu
  • Quinazoline heterocyclic compound as EGFR kinase inhibitor and preparation and application thereof
    Patent number: 10106508
    Abstract: The present invention relates to an N-substituted-phenyl-5-substituted-alkoxy-2,3-dihydro-[1,4]dioxane[2,3-f]quinazolin-10-amine (I) or 4-substituted-arylamino-6-substituted-alkyl-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one (II) type compounds, a preparation method thereof and an application thereof as an inhibitor for epidermal growth factor receptor (EGFR) (comprising some mutant forms of EGFR) to treat cancer. These compounds and salts thereof can be used to treat or prevent various cancer diseases.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 23, 2018
    Assignee: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Wang Sheng, Leifu Yang, Zhiyong Pan
  • QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF
    Publication number: 20170355683
    Abstract: The present invention relates to an N-substituted-phenyl-5-substituted-alkoxy-2,3-dihydro-[1,4]dioxane[2,3-f]quinazolin-10-amine (I) or 4-substituted-arylamino-6-substituted-alkyl-6H-[1,4]oxazino[3,2-g]quinazoline-7(8H)-one (II) type compounds, a preparation method thereof and an application thereof as an inhibitor for epidermal growth factor receptor (EGFR) (comprising some mutant forms of EGFR) to treat cancer. These compounds and salts thereof can be used to treat or prevent various cancer diseases.
    Type: Application
    Filed: January 12, 2016
    Publication date: December 14, 2017
    Applicant: BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
    Inventors: Wang SHENG, Leifu YANG, Zhiyong PAN